Abetimus
| Clinical data | |
|---|---|
| ATC code | L04AA22 (WHO) |
| Identifiers | |
| CAS Number |
169147-32-4  |
| ChemSpider | none |
 (what is this?) (verify) | |
Abetimus is an immunosuppressant.[1] It is a synthetic biological called a tolerogen. It is made of four double-stranded oligodeoxyribonucleotides that are attached to a carrier platform and are designed to block specific B-cell anti double stranded DNA antibodies.[2] It may also complex anti dsDNA antibodies together, therefore disabling them. This way Abetimus is supposed to help treat Systemic Lupus Erythematosus and specifically nephritis.
References
- ↑ (not listed) (2003). "Abetimus: Abetimus sodium, LJP 394". BioDrugs. Adis. 17 (3): 212–215. doi:10.2165/00063030-200317030-00009. ISSN 1173-8804. PMID 12749759.
- ↑ Wallace, Daniel J. (January 2001), "Clinical and pharmacological experience with LJP-394", Expert Opinion on Investigational Drugs, Informa, 10 (1), pp. 111–117, doi:10.1517/13543784.10.1.111, ISSN 1354-3784, PMID 11116284, retrieved 2 April 2011
This article is issued from Wikipedia - version of the 9/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.